1 active not recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Active not recruiting 1 |
Follow EGFR Exon 19 Deletion: new trials by email Literature Review of EGFR Exon 19 Deletion trials Research Report on EGFR Exon 19 Deletion
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy Patritumab Deruxtecan, Platinum-based chemotherapy - Nonsquamous Non-small Cell Lung Cancer, EGFR L858R | Phase 3 | Active not recruiting | Daiichi Sankyo | 586 | 2022-07-08 | 2026-08-27 |
Platinum Compounds (1) · patritumab deruxtecan (1)
Daiichi Sankyo (1)
Australia (1) · Austria (1) · Belgium (1) · Canada (1) · China (1) · France (1) · Germany (1) · Hong Kong (1) · Italy (1) · Japan (1) · Netherlands (1) · Norway (1) · Poland (1) · Portugal (1) · Singapore (1)
2023 (1)